IL-6 inhibition and infection: treating patients with tocilizumab
Author:
Open Access
- 7 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 51 (5) , 769-770
Abstract
Is there a greater risk of infections?Keywords
This publication has 6 references indexed in Scilit:
- Risk of infections in rheumatoid arthritis patients treated with tocilizumabRheumatology, 2011
- High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?Nature Reviews Rheumatology, 2009
- Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy studyArthritis & Rheumatism, 2008
- Impaired immune and acute-phase responses in interleukin-6-deficient miceNature, 1994